Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 18,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002920 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,112,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · derivative · entry 5 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Tax withholdingCommon Stock | 367 | $42.83 | $15,718.61 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,504 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:45 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002921 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002919 · doc4.xml · derivative · entry 6 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 2,833 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Mackey Edward FEVP, Operations
|
Tax withholdingCommon Stock | 832 | $42.83 | $35,634.56 |
DisclosureSEC source: 0001225208-22-002919 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,435 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionCommon Stock | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002919 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Exercise / conversionRestricted Stock Units · Derivative | 4,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002918 · doc4.xml · derivative · entry 7 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 4,166 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Tax withholdingCommon Stock | 2,056 | $42.83 | $88,058.48 |
DisclosureSEC source: 0001225208-22-002918 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,198 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Exercise / conversionCommon Stock | 4,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002918 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionRestricted Stock Units · Derivative | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · derivative · entry 5 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 2,250 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 661 | $42.83 | $28,310.63 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,153 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002916 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002917 · doc4.xml · derivative · entry 5 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,500 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
Tax withholdingCommon Stock | 441 | $42.83 | $18,888.03 |
DisclosureSEC source: 0001225208-22-002917 · doc4.xml · nonDerivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,590 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:44 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002917 · doc4.xml · nonDerivative · entry 1 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Exercise / conversionRestricted Stock Units · Derivative | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002915 · doc4.xml · derivative · entry 6 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 2,833 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Tax withholdingCommon Stock | 1,185 | $42.83 | $50,753.55 |
DisclosureSEC source: 0001225208-22-002915 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,872 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002915 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · derivative · entry 5 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 1,000 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 332 | $42.83 | $14,219.56 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,960 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · derivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 4,583 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 2,033 | $42.83 | $87,073.39 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,727 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 4,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002913 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:31 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
GrantStock Option (Right to Buy) · Derivative | 15,367 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002683 · doc4.xml · derivative · entry 5 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,367 Underlying: Common Stock · 15,367 shares Expires 2032-02-16 F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:31 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
GrantRestricted Stock Units · Derivative | 5,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002683 · doc4.xml · derivative · entry 4 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,374 Underlying: Common Stock · 5,374 shares Expires 2026-02-16 F4 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:42 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantStock Option (Right to Buy) · Derivative | 25,882 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002703 · doc4.xml · derivative · entry 5 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,882 Underlying: Common Stock · 25,882 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:42 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
GrantRestricted Stock Units · Derivative | 9,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002703 · doc4.xml · derivative · entry 4 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,051 Underlying: Common Stock · 9,051 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:38 UTC |
Sorenson John BradleySVP, Global Supply Chain
|
GrantStock Option (Right to Buy) · Derivative | 14,558 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002701 · doc4.xml · derivative · entry 6 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,558 Underlying: Common Stock · 14,558 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:38 UTC |
Sorenson John BradleySVP, Global Supply Chain
|
GrantRestricted Stock Units · Derivative | 5,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002701 · doc4.xml · derivative · entry 5 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,091 Underlying: Common Stock · 5,091 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:37 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
GrantStock Option (Right to Buy) · Derivative | 24,264 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002699 · doc4.xml · derivative · entry 5 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,264 Underlying: Common Stock · 24,264 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:37 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
GrantRestricted Stock Units · Derivative | 8,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002699 · doc4.xml · derivative · entry 4 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,486 Underlying: Common Stock · 8,486 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:34 UTC |
Pierce David AEVP Pres MedSurg
|
SaleCommon Stock | 1,956 | $43.81 | $85,692.36 |
DisclosureSEC source: 0001225208-22-002694 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-l trading plan. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:25 UTC |
Monson JonathanVP, Global Controller and CAO
|
GrantStock Option (Right to Buy) · Derivative | 13,180 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002679 · doc4.xml · derivative · entry 5 Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,180 Underlying: Common Stock · 13,180 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:25 UTC |
Monson JonathanVP, Global Controller and CAO
|
GrantRestricted Stock Units · Derivative | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002679 · doc4.xml · derivative · entry 4 Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,960 Underlying: Common Stock · 3,960 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:28 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantStock Option (Right to Buy) · Derivative | 21,029 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,029 Underlying: Common Stock · 21,029 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:28 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
GrantRestricted Stock Units · Derivative | 7,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · derivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,354 Underlying: Common Stock · 7,354 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:24 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantStock Option (Right to Buy) · Derivative | 33,970 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · derivative · entry 5 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,970 Underlying: Common Stock · 33,970 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:24 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantRestricted Stock Units · Derivative | 11,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · derivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,880 Underlying: Common Stock · 11,880 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:21 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
GrantStock Option (Right to Buy) · Derivative | 12,941 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · derivative · entry 5 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,941 Underlying: Common Stock · 12,941 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:21 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
GrantRestricted Stock Units · Derivative | 4,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · derivative · entry 4 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,525 Underlying: Common Stock · 4,525 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 186,029 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002673 · doc4.xml · derivative · entry 5 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,029 Underlying: Common Stock · 186,029 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantRestricted Stock Units · Derivative | 65,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002673 · doc4.xml · derivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,059 Underlying: Common Stock · 65,059 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of Common Stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of Common Stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:12 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
GrantStock Option (Right to Buy) · Derivative | 45,294 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002669 · doc4.xml · derivative · entry 8 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,294 Underlying: Common Stock · 45,294 shares Expires 2032-02-16 F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:12 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
GrantRestricted Stock Units · Derivative | 15,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002669 · doc4.xml · derivative · entry 7 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,840 Underlying: Common Stock · 15,840 shares Expires 2026-02-16 F6 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:06 UTC |
Carruthers WendySVP, Human Resources
|
GrantStock Option (Right to Buy) · Derivative | 23,455 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · derivative · entry 5 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,455 Underlying: Common Stock · 23,455 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:06 UTC |
Carruthers WendySVP, Human Resources
|
GrantRestricted Stock Units · Derivative | 8,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · derivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,203 Underlying: Common Stock · 8,203 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:09 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
GrantStock Option (Right to Buy) · Derivative | 17,794 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002667 · doc4.xml · derivative · entry 5 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,794 Underlying: Common Stock · 17,794 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:09 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
GrantRestricted Stock Units · Derivative | 6,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002667 · doc4.xml · derivative · entry 4 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,223 Underlying: Common Stock · 6,223 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.